8.89
+0.2354(+2.72%)
Currency In USD
Address
51 West 52nd Street
New York City, NY 10019
United States of America
Phone
844 689 3939
Website
Sector
Healthcare
Industry
Biotechnology
Employees
42
First IPO Date
August 02, 2006
| Name | Title | Pay | Year Born |
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary & Director | 856,100 | 1966 |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer | 209,527 | 1981 |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development | 0 | N/A |
| Clint Tomlinson | Vice President of Corporate | 0 | N/A |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer | 0 | N/A |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development | 0 | N/A |
| Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. | Senior Vice President & Head of Research and Development | 0 | N/A |
| Dr. Kun Jin Ph.D. | Head of Biostatistics | 0 | N/A |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.